| Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. | |
MedLine Citation:
|
PMID: 21995758 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the effect of anti-VEGF (bevacizumab) injection to the posterior chamber (BIPC) behind the iris combined with seton implantation in treatment of neovascular glaucoma (NVG). METHODS: Twenty-eight eyes with NVG who underwent BIPC, prospectively evaluated. Anterior segment photographs were taken for grading of neovascularization on anterior segment in pretreatment period and at each follow-up. Grading and regression of rubeosis iridis was classified according to Teich and Walsh grading system and glaucoma filtration surgery with drainage device was performed following BIPC. RESULTS: The mean pre-BIPC IOP was 39.71 ± 7.09 mmHg, post-BIPC IOP in the 1st, 2nd day, 1st week, 1st, 3rd, 6th month were 19.7 ± 8.9 mmHg, 13.5 ± 6.7 mmHg, 9.9 ± 3.4 mmHg, 13.07 ± 5.3 mmHg, 16.6 ± 5.03 mmHg, 18.5 ± 3.8 mmHg, respectively. Twenty seven eyes underwent seton implantation surgery. No one had anterior segment bleeding during surgery. The pre-BIPC grades were Grade 4: 67.58%, Grade 3: 28.57%, Grade 2: 3.57%, no one had Grade 1or Grade 0, while post BIPC grade were at the 1st week Grade 1: 64.28%, Grade 0: 35.71%, no one had Grade 2 or more, at 1st month Grade 2: 3.57%, Grade 1: 39.28%, Grade 0: 57.14%, at 3rd month Grade 2: 17.85% Grade 1: 28.57%, Grade 0: 53.57%, no one had Grade 3 or more both in first and the third month, at 6th month Grade 3: 7.14%, Grade 2: 28.57%, Grade 1: 42.85%, Grade 0: 21.42%. and no one had Grade 4. CONCLUSION: Significant reduction of NV was observed during the first week. Minimal increasement was seen in third month, significant regression effect persisted for 6 months. BIPC inhibited the peroperative risk of anterior segment bleeding, increased the surgical comfort and prevented the failure of filtration procedure by inhibiting reproliferation. |
Authors:
|
Ayse Gul Kocak Altintas; Hasan Basri Arifoglu; Esen Tutar; Gultekin Koklu; Pehmen Yasin Ozcan |
Related Documents
:
|
8861308 - Radiosurgery: a minimally interventional alternative to microsurgery in the management ... 23748208 - Increased incidence of esophageal thermal lesions using the second-generation 28mm cryo... 1083228 - Arteriovenous malformations of the gastrointestinal tract. 2096608 - Treatment of intracranial meningiomas in patients over 70 years old. 9373658 - Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine an... 21729308 - The efficacy of hypotonic and near-isotonic saline for parenteral fluid therapy given a... |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2011-10-13 |
Journal Detail:
|
Title: Cutaneous and ocular toxicology Volume: 31 ISSN: 1556-9535 ISO Abbreviation: Cutan Ocul Toxicol Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-05-17 Completed Date: 2012-09-18 Revised Date: 2013-05-27 |
Medline Journal Info:
|
Nlm Unique ID: 101266892 Medline TA: Cutan Ocul Toxicol Country: England |
Other Details:
|
Languages: eng Pagination: 124-7 Citation Subset: IM |
Affiliation:
|
S.B. Ulucanlar Eye Research and Education Hospital, Ophthalmology Department, Ankara, Turkey. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angiogenesis Inhibitors / administration & dosage* Anterior Chamber Antibodies, Monoclonal, Humanized / administration & dosage* Female Glaucoma, Neovascular / drug therapy* Humans Injections Iritis / drug therapy Male Middle Aged Suture Techniques |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Secondary postpartum hemorrhage due to uterine artery pseudoaneurysm rupture in von Willebrand disea...
Next Document: Assessment of home environments with a fungal index using hydrophilic and xerophilic fungi as biolog...